 Japans Ministry of Health, Labor, and Welfare MHLW has approved Astellas Pharma Incs OTC: ALPMF Padcev enfortumab vedotin for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. Enfortumab vedotin is the first and only antibody-drug conjugate approved in Japan for patients with advanced urothelial cancer. 